1999
DOI: 10.1016/s0165-5876(99)00279-7
|View full text |Cite
|
Sign up to set email alerts
|

Cimetidine treatment for recurrent respiratory papillomatosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
20
0

Year Published

2004
2004
2023
2023

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 53 publications
(20 citation statements)
references
References 18 publications
0
20
0
Order By: Relevance
“…Only 7.7% of responding consultants reported the use of antireflux medication, compared with 15% in the ASPO survey, despite studies showing beneficial effects in reducing the rate of disease recurrence and soft tissue complications [18].…”
Section: Discussionmentioning
confidence: 83%
See 1 more Smart Citation
“…Only 7.7% of responding consultants reported the use of antireflux medication, compared with 15% in the ASPO survey, despite studies showing beneficial effects in reducing the rate of disease recurrence and soft tissue complications [18].…”
Section: Discussionmentioning
confidence: 83%
“…Eight departments are treating 27 (26.2%) patients with distal spread of the disease in the trachea (18), trachea and bronchi (5), trachea, bronchi, and lung parenchyma (4). Two of those are treated with surgery alone, whereas six have surgery and adjuvant therapy (cidofovir, interferon and indole 3 carbinol).…”
Section: Resultsmentioning
confidence: 99%
“…26 CIM has also been used to treat juvenile respiratory papillomatosis, which is caused by infective agents found in HPV-6 and -11. 27 Because the association of papilloma with HPVs is well known, immunomodulating agents may play key roles in tumor eradication because cellular immunity is important for the antiviral defense mechanism. CIM achieves immunomodulation by inhibiting H 2 receptors on suppressor T cells.…”
Section: Discussionmentioning
confidence: 99%
“…Patients with refractory disease have an abnormal amount and balance of cytokines [17]. Systemic administration with cimetidine, a common H2 receptor antagonist used to treat GERD, has been shown to have some benefit as adjuvant therapy for RRP [18]. At high doses, the drug has immunomodulatory properties, shifting the balance of helper T cells (Th1 > Th2) and stimulating the inhibition of intracellular viral infections [19].…”
Section: Discussionmentioning
confidence: 99%